Merck & Company Inc (MRK)vsStevanato Group SpA (STVN)
MRK
Merck & Company Inc
$144.52
-2.23%
HEALTHCARE · Cap: $362.27B
STVN
Stevanato Group SpA
$15.53
-1.71%
HEALTHCARE · Cap: $3.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 5298% more annual revenue ($67.38B vs $1.25B). STVN leads profitability with a 11.3% profit margin vs 3.6%. STVN appears more attractively valued with a PEG of 1.70. STVN earns a higher WallStSmart Score of 59/100 (C).
MRK
Hold42
out of 100
Grade: D
STVN
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-74.0%
Fair Value
$84.93
Current Price
$144.52
$59.59 premium
Margin of Safety
+67.9%
Fair Value
$48.58
Current Price
$15.53
$33.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 35.2%
Generating 5.5B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Elevated debt levels
Expensive relative to growth rate
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : STVN
The strongest argument for STVN centers on Debt/Equity, Price/Book.
Bear Case : MRK
The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : STVN
The primary concerns for STVN are PEG Ratio, Piotroski F-Score.
Key Dynamics to Monitor
STVN carries more volatility with a beta of 0.80 — expect wider price swings.
STVN is growing revenue faster at 7.6% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
STVN scores higher overall (59/100 vs 42/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Stevanato Group SpA
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stevanato Group SpA (STVN) is a leading global provider of advanced drug delivery systems, specializing in innovative glass and polymer packaging solutions designed for injectable medications used by the pharmaceutical and biotechnology industries. With a steadfast focus on quality, sustainability, and the adoption of cutting-edge technologies, Stevanato is well-positioned to benefit from the burgeoning demand within the biopharmaceutical sector. The company’s dedication to enhancing the efficiency and reliability of drug administration makes it an attractive proposition for institutional investors looking for opportunities in healthcare innovation and sustainable growth.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?